Alembic Pharmaceuticals on Thursday said its consolidated net profit declined by 29 per cent to Rs 122 crore in the December quarter.
The Vadodara-based drug maker had reported a net profit of Rs 172 crore in the October-December quarter of last fiscal.
Revenue from operations rose to Rs 1,509 crore in the period under review from Rs 1,272 crore in the year-ago period, Alembic Pharmaceuticals said in a statement.
"The company witnessed top-line growth across all the verticals. In particular, the API business outperformed with a 65 per cent growth during the quarter," Alembic Pharmaceuticals Managing Director Pranav Amin stated.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app